Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Michael Dennis, MD, Nigel H. Russell, MD, Nicki Panoskaltsis, MD, Claire Jane Hemmaway, MD, Donald Milligan, MD, Richard E Clark, MBBS MD, Robert K. Hills, MA MSc DPhil, Alan K Burnett, MD

Blood (2014) 124 (21): 3747.

https://doi.org/10.1182/blood.V124.21.3747.3747

Published: 2014

Journal Articles

Epirubincin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568)

Kai Xue, MD, Zhang Qunling, MD, Xiaojian Liu, MD, Junning Cao, MD, Xiaonan Hong, MD, Ye Guo, MD

Blood (2013) 122 (21): 372.

https://doi.org/10.1182/blood.V122.21.372.372

Published: 2013

Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD

Blood (2010) 116 (21): 1766.

https://doi.org/10.1182/blood.V116.21.1766.1766

Published: 2010

Journal Articles

Transfusional Iron Overload: An Underappreciated Danger in AML Patients?

Jacob Rozmus, MD, FRCPC, Louis D. Wadsworth, MBChB, FRCP, John K. Wu, MBBS, FRCPC

Blood (2009) 114 (22): 4133.

https://doi.org/10.1182/blood.V114.22.4133.4133

Published: 2009

Journal Articles

Health Outcomes in Childhood Cancer Survivors: Screening for Anthracycline-Induced Cardiac Toxicity.

Jeffrey R. Andolina, MD, Kimberley Dilley, MD, MPH

Blood (2009) 114 (22): 70.

https://doi.org/10.1182/blood.V114.22.70.70

Published: 2009

Journal Articles

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Edward Agura, MD, R. Brian Berryman, MD, Laura Brougher, RN, Barry Cooper, MD, Andrew De Leon, RPh, Joseph Fay, MD, Houston Holmes, MD, Christopher Maisel, MD, Arturo Molina, MD, Luis Pineiro, MD, Giovanna Saracino, MD, Mirjana Tadic-Ovcina, MD, Estil Vance, MD

Blood (2006) 108 (11): 1951.

https://doi.org/10.1182/blood.V108.11.1951.1951

Published: 2006

NARROW

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Epirubincin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568)

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Transfusional Iron Overload: An Underappreciated Danger in AML Patients?

Health Outcomes in Childhood Cancer Survivors: Screening for Anthracycline-Induced Cardiac Toxicity.

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Email alerts

ASH Publications

American Society of Hematology

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Epirubincin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568)

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Transfusional Iron Overload: An Underappreciated Danger in AML Patients?

Health Outcomes in Childhood Cancer Survivors: Screening for Anthracycline-Induced Cardiac Toxicity.

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only